C-reactive protein: albumin ratio in patients with resectable intrahepatic cholangiocarcinoma

T. Matsumoto, S. Itoh, T. Yoshizumi, T. Kurihara, S. Yoshiya, Y. Mano, kazuki takeishi, Noboru Harada, T. Ikegami, Y. Soejima, H. Baba, M. Mori

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Background: The C-reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). Methods: This was a single-centre retrospective study of patients who underwent surgery for ICC in a university hospital in Japan between 1998 and 2018. CAR, Glasgow Prognostic Score (GPS) and modified GPS (mGPS) were calculated. Their correlation with recurrence-free survival (RFS) and overall survival (OS) was analysed with Cox proportional hazards models. Results: Seventy-two patients were included in the study. Patients were divided into two groups according to the optimal CAR cut-off value of 0·02. CAR above 0·02 was associated with higher carbohydrate antigen 19-9 levels (20·5 versus 66·1 units/ml for CAR of 0·02 or less; P = 0·002), larger tumour size (3·2 versus 4·4 cm respectively; P = 0·031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0·041). RFS and OS were shorter in patients with CAR above 0·02: hazard ratio (HR) 4·31 (95 per cent c.i. 2·02 to 10·63) and HR 4·80 (1·85 to 16·40) respectively. In multivariable analysis CAR above 0·02 was an independent prognostic factor of RFS (HR 3·29 (1·33 to 8·12); P < 0·001), but not OS. Conclusions: CAR was associated with prognosis in patients who had hepatic resection for ICC.

Original languageEnglish
Pages (from-to)1146-1152
Number of pages7
JournalBJS open
Issue number6
Publication statusPublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Surgery


Dive into the research topics of 'C-reactive protein: albumin ratio in patients with resectable intrahepatic cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this